MET IHC testing, which helps identify patients with locally advanced or metastatic non-squamous NSCLC who exhibit high c-Met protein overexpression and may be eligible for a new targeted treatment. 2 ...

Researchers tested more than 65,000 patients with more than 30 solid tumor types and found the rate of HER2 positivity was about 3%.

Caris Life Sciences Provides MET Immunohistochemistry Testing as Standard of Care for Non-Squamous Non-Small Cell Lung Cancer Patients Provided by PR Newswire May 12, 2025, 3:30:00 AM ...

If you get an IHC test for HER2 receptors, the lab gives your doctor a number for a result: 0 or 1+ means your breast cancer doesn’t have receptors for HER2. Your doctor calls this HER2-negative.

The IHC method, which utilizes a monoclonal antibody that recognizes and attaches to prions, the misfolded proteins that cause CWD, triggers a staining reaction and is considered the gold standard ...

However, in their practices, oncologists use IHC much more often. That suggests that a change in testing could result in more patients receiving the right treatment for their cancers.

Tempus Next Launches New Algorithm to Close Care Gaps in Guideline-Directed IHC Testing, Starting with HER2 Aug. 01, 2024 8:30 AM ET Tempus AI, Inc. (TEM) ...

Four PD-L1 IHC (22C3, 28-8, SP142, SP263) tests, which help identify patients who may benefit from immunotherapies; PD-L1 IHC testing has become a crucial tool for personalizing treatment ...

The Texas A&M Veterinary Medical Diagnostic Laboratory has resumed immunohistochemistry (IHC) testing for chronic wasting disease after a national supply shortage of reagents grinded the process ...

Foundation Medicine, Inc., a genomics company committed to transforming cancer care , today announced that it has expanded its immunohistochemistry (IHC) test offerings to include MET IHC testing ...